高级检索
当前位置: 首页 > 详情页

Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2-advanced or metastatic breast cancer in China

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Dept Clin Pharmacol, Hosp 4, Shijiazhuang, Peoples R China [2]Hebei Med Univ, Dept Pharm, Hosp 4, Shijiazhuang, Peoples R China [3]Hebei Med Univ, Dept Pharm, Shijiazhuang, Peoples R China [4]Hebei Med Univ, Dept Clin Pharm, Hosp 3, Shijiazhuang, Peoples R China [5]Peking Univ, Int Res Ctr Med Adm, Beijing, Peoples R China [6]Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China [7]Hebei Med Univ, Dept Breast Ctr, Hosp 4, Shijiazhuang, Peoples R China [8]Hebei Med Univ, Dept Med Insurance, Hosp 4, Shijiazhuang, Peoples R China
出处:
ISSN:

关键词: CDK4/6 inhibitors Fulvestrant Cost-effectiveness HR-positive/HER2-negative Breast cancer China

摘要:
Hormone receptor HR-positive/HER2-negative (HR+/HER2-) breast cancer is the most common subtype in China, representing 60-70% of cases, with a rising incidence due to aging demographics and lifestyle changes. CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib have been proven effective in treating HR+/HER2 - advanced or metastatic breast cancer (ABC/MBC), though they may increase healthcare costs. This study aims to compare the efficacy, safety and cost-effectiveness of CDK4/6 inhibitors for the second-line treatment of HR+/HER2 - ABC/MBC from the Chinese healthcare perspective. A cohort-based partitioned survival model was utilized, drawing on the survival data published from PALOMA-3, MONALEESA-3 and MONARCH-2 trials. Costs, and quality-adjusted life years (QALYs) were used to calculate the incremental cost-effectiveness ratio (ICER) over a 15-year time horizon. Deterministic and probabilistic sensitivity analyses were performed to assess the robustness of the model results. In the base-case analysis, the model estimated health benefits to be 2.10 QALYs for palbociclib plus fulvestrant (PAL + FUL), 2.55 QALYs for ribociclib plus fulvestrant (RIB + FUL), and 2.60 QALYs for abemaciclib plus fulvestrant (ABE + FUL), with corresponding costs of $34,423, $41,119, and $48,019. Compared with PAL + FUL, the ICERs were $27,161 per QALY for ABE + FUL and $15,073 per QALY for RIB + FUL. The robustness of these findings was confirmed through uncertainty analyses. Among the three strategies, the most cost-effective probabilities of PAL + FUL, RIB + FUL and ABE + FUL were 0%, 99.8%, and 0.2% under the willingness-to-pay (WTP) threshold of 3 times per-capita gross domestic product ($37,738) in China. This study indicated that both RIB + FUL and ABE + FUL are cost-effective at the WTP threshold compared with PAL + FUL. Notably, RIB + FUL offers the greatest cost-effective advantage for the second-line treatment of HR+/HER2 - ABC/MBC among these three CDK4/6 inhibitors.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2025]版:
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
最新[2025]版:
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
JCR分区:
出版当年[2024]版:
Q1 MULTIDISCIPLINARY SCIENCES
最新[2024]版:
Q1 MULTIDISCIPLINARY SCIENCES

影响因子: 最新[2024版] 最新五年平均 出版当年[2025版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Dept Clin Pharmacol, Hosp 4, Shijiazhuang, Peoples R China
通讯作者:
通讯机构: [1]Hebei Med Univ, Dept Clin Pharmacol, Hosp 4, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号